Opportunities and challenges for utilization of nanoparticles as bioactive drug carriers for the targeted treatment of cancer

Edina Vranić, Ognjenka Rahić, Jasmina Hadžiabdić, Alisa Elezović, Dušanka Bošković



Nanotechnology has a great potential for improving many areas of research and its applications, like nanoscale phenomena and processes, nanomaterials, nanoscale devices and instrumentation research.

Nanoparticles, that are currently used, demonstrate many desirable properties for cancer management, considering their ability to accumulate in the specific parts of pathological areas and provide controlled drug release.

Pharmaceutical nanocarriers can be used as a part of drug delivery systems for the purposes of therapy, diagnosis and imaging. Methods for nanoparticle manufacturing are: spray drying, aerosol flow reactor, mechanical methods (milling, homogenization under high pressure), precipitation techniques, techniques using supercritical fluids, methods for emulsion preparation and freezing (lyophilization).

Future trends in the development of nanotechnology are expected to go towards additional decrease in dimensions of active and auxiliary compounds. The only way to achieve this is to combine methods used in medicine, engineering, materials studying, information technologies and physics.

Keywords: nanoparticles, cancer, drug delivery

Full Text:



Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles

(SLN) for controlled drug delivery - a review of the state of

the art. Eur J Pharm Biopharm 2000; 50(1):161-177.

des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V.

Nanoparticles as potential oral delivery systems of proteins

and vaccines: a mechanistic approach. J Control Release

; 116(1):1-27.

Li Z, Jiang H, Xu C, Gu L. A review: Using nanoparticles to

enhance absorption bioavailability of phenolic phytochemicals.

Food Hydrocolloid 2015; 43:153-164.

Ferrari M. Cancer nanotechnology: opportunities and challenges.

Nature Rev Cancer 2005; 5(3):161-171.

Chen H, Zhen Z, Todd T, Chu PK, Xie J. Nanoparticles

for improving cancer diagnosis. Mater Sci Eng R Rep 2013;


Jain RK. Transport of molecules in the tumor interstitium: a

review. Cancer Res 1987; 47(12):3039-3051.

Jain RK. Delivery of molecular medicine to solid tumors:

lessons from in vivo imaging of gene expression and function.

J Control Release 2001; 74(1-3):7-25.

Seymour LW. Passive tumor targeting of soluble macromolecules

and drug conjugates. Crit Rev Ther Drug Carrier Syst

; 9(2):135-187.

Baban D, Seymour LW. Control of tumor vascular permeability.

Adv Drug Deliv Rev 1998; 34(1):109-119.

Maeda H. The enhanced permeability and retention (EPR)

effect in tumor vasculature: the key role of tumor-selectivemacromolecular

drug targeting. Adv Enzyme Regul

; 41:189-207.

Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L,

Torchilin VP, Jain RK. Regulation of transport pathways in

tumor vessels: role of tumor type and microenvironment.

Proc Natl Acad Sci USA 1998; 95(8):4607-4612.

Yuan F, Dellian M, Fukumura D, Leuning M, Berk DD,

Yorchilin VP, Jain RK. Vascular permeability in a human tumor

xenograft: molecular size dependence and cutoff size.

Cancer Res 1995; 55(17):3752-3756.

Unezaki S, Maruyama K, Hosoda J-I, Nagae I, Koyanagi Y,

Nakata M, Ishida O, Iwatsuru M, Tsuchiya S. Direct measurement

of the extravasation of polyethyleneglycol-coated

liposomes into solid tumor tissue by in vivo fluorescence

microscopy. Int J Pharm 1996; 144(1):11-17.

Links M, Brown R. Clinical relevance of the molecular

mechanisms of resistance to anti-cancer drugs. Expert Rev

Mol Med 1999; 1:1-21.

Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer-

mechanisms, reversal using modulators of MDR and the

role of MDR modulators in influencing the pharmacokinetics

of anticancer drugs. Eur J Pharm Sci 2000; 11(4):265-

Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer

therapy and diagnosis. Adv Drug Deliv Rev 2002; 54(5):24-

Simões MCF, Sousa JJS, Pais AACC. Skin cancer and

new treatment perspectives: A review. Cancer Lett 2015;


Mehnert W, Mäder K. Solid lipid nanoparticles: production,

characterization and applications. Adv Drug Deliv Rev

; 47(2-3):165-196.

Thukral DK, Dumoga S, Mishra AK. Solid lipid nanoparticles:

promising therapeutic nanocarriers for drug delivery.

Curr Drug Deliv 2014; 11(6):771-791.

Hoshino Y, Koide H, Furuya K, Haberaecker WW 3rd, Lee

SH, Kodama T. et al. The rational design of a synthetic polymer

nanoparticle that neutralizes a toxic peptide in vivo.

Proc Nat Acad Sci USA 2012; 109(1):33-38.

Parhi R, Suresh P. Preparation and characterization of solid

lipid nanoparticles-a review. Curr Drug Discov Technol

; 9(1):2-16.

Puglia C, Bonina F. Lipid nanoparticles as novel delivery

systems for cosmetics and dermal pharmaceuticals. Expert

Opin Drug Deliv 2012; 9(4):429-441.

Muller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles

(SLN and NLC): present state of development and

industrial applications. Curr Drug Discov Technol 2011;


De Jong WH, Borm PJ. Drug delivery and nanoparticles:

applications and hazards. Int J Nanomedicine 2008;


Akbarzadeh A, Samiei M, Davaran S. Magnetic nanoparticles:

preparation, physical properties, and applications in

biomedicine. Nanoscale Res Lett 2012; 7(1):1-13.

Jain S, Hirst DG, O’Sullivan JM. Gold nanoparticles as

novel agents for cancer therapy. British J Radiol 2012;


Slastnikova TA, Rosenkranz AA, Gulak PV, Schiffelers RM,

Lupanova TN, Khramtsov YV, et al. Modular nanotransporters:

a multipurpose in vivo working platform for targeted

drug delivery. Int J Nanomedicine 2012; 7:467-482.

Das S, Dowding JM, Klump KE, McGinnis JF, Self W, Seal

S. Cerium oxide nanoparticles: applications and prospects in

nanomedicine. Nanomedicine 2013; 8(9):1483-1508.

Alili L, Sack M, von Montfort C, Giri S, Das S, Carroll

KS, et al. Downregulation of tumor growth and invasion

by redox-active nanoparticles. Antioxid Redox Signal 2013;


Siddiqui IA, Adhami VM, Chamcheu JC, Mukhtar H. Impact

of nanotechnology in cancer: emphasis on nanochemoprevention.

Int J Nanomedicine 2012; 7:591-605.

Orive G, Anitua E, Pedraz JL, Emerich DF. Biomaterials for

promoting brain protection, repair and regeneration. Nat

Rev Neurosci 2009; 10(9):682-692.

Uchechi O, Ogbonna JDN, Attama AA. Nanoparticles for

dermal and transdermal drug delivery. In; Sezer AD (ed).

Application of nanotechnology in drug delivery. Rijeka: In-

Tech; 2014, pp. 193-235.

Pascau SI, Arrowsmith RL, Bayly SR, Brayshaw S, Hu Z.

Towards nanomedicines: design protocols to assemble, visualize

and test carbon nanotube probes for multi-modality biomedical

imaging. Phil Trans R Soc 2010; 368:3683-3712.

Linemann T, Thomsen LB, du Jardin KG, Laursen JC, Jensen

JB, Lichota J, et al. Development of a novel lipophilic, magnetic

nanoparticle for in vivo drug delivery. Pharmaceutics

; 5:246-260.

Scott MC, Chen C-C, Macklenburg M, Zhu C, Xu R, Ercius

P, et al. Electron tomography at 2.4-ångström resolution.

Nature 2012; 483:444-447.

Pelletier DA, Suresh AK, Holton GA, McKeown CK, Wang

W, Gu B, et al. Effects of engineered cerium oxide nanoparticles

on bacterial growth and viability. Appl Environ Microbiol

; 76(24):7981-7989.

Frasco MF, Chaniotakis N. Bioconjugated quantum dots as

fluorescent probes for bioanalytical applications. Anal Biochem

Chem 2010; 396:229-240.


  • There are currently no refbacks.